Tag: amgen
-
Regeneron CEO says Amgen not putting patients first in patent dispute
A federal judge last week handed Regeneron and its partner Sanofi a stunning setback by banning sales of their LDL-lowering medicine Praluent, finding it infringed patents held by Amgen on its Repatha cholesterol drug. Regeneron and Sanofi were given 30 days before the ban takes effect to give them time to appeal.
-
FDA approves Amgen’s copy of AbbVie arthritis drug Humira
The U.S. Food and Drug Administration on Friday approved Amgen Inc’s biosimilar version of AbbVie’s top-selling arthritis drug, Humira. The drug, Amjevita, known also as adalimumab-atto, was approved to treat rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and other conditions. Amjevita is the fourth biosimilar to be approved by the FDA and is expected to…
-
FDA approves Amgen’s copy of AbbVie arthritis drug Humira
The U.S. Food and Drug Administration on Friday approved Amgen Inc’s biosimilar version of AbbVie’s top-selling arthritis drug, Humira. The drug, Amjevita, known also as adalimumab-atto, was approved to treat rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and other conditions. Amjevita is the fourth biosimilar to be approved by the FDA and is expected to…
-
Boxing-Fury pulls out of Klitschko rematch through injury
BERLIN, Sept 23 (Reuters) – The world heavyweight title rematch between champion Tyson Fury and Ukrainian Vladimir Klitschko on Oct. 29 has been called off for a second time with the Briton ruled “medically unfit”. “Tyson has this week been declared medically unfit to fight,” Fury’s promoters Hennessy Sports said in a brief statement on…